Don't expect that to change this year. It is going to be stuck in the 5 or 6 range before it breaks out to $20 to $30 next year (around Sept 2016)
in summer 2013 its run to 20 and back to ten with nothing thats all i will said the potence is like tubulysin this can fly to 30 or hold 6 range but i see 20 first than buyout 50-100$ iam here thats safe nothing else
Are you seriously suggesting that the company will hold off starting trials due to it being vacation season? You have an interesting thought process.
Sentiment: Strong Buy
Here are some basic differences that I'm aware of. Anyone is welcome to correct me if I'm wrong. ECYT makes small molecules, which can penetrate solid tumors. CART works against blood borne cancers only, so far. CART also destroys the body's B cells, which means the patient has to compensate for the lost immune function for the rest of their lives with injections. CART is expensive and small molecules are much less expensive. Effectiveness would probably go to CART right now, but tubulysin and other drug warheads ECYT could take advantage of are extremely cytotoxic.
ECYT isn't old method, but BLUE / JUNO tech. is comparatively newer.
ECYT is working on delivering toxic drugs selectively to the tumors (google Tumor Snipers) so as to kill cancerous cells with minimal drug going to healthy cells, thereby minimizing side effects.
JUNO / BLUE take a very different approach. They don't selectively deliver a toxic drug. They take stem cells / TCells from your blood, reprogram it through genetic modification so that those cells get the ability to identify and kill the trojan/cancerous cells.
All 3 can win. Cancer is a $100bn / year business. Good drugs/ therapies will win. All 3 you mentioned have good potential.
Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that data featuring Endocyte’s SMDC, EC1456 will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 29 – June 2, 2015, in Chicago.
The EC1456 poster shows that EC1456 is generally well tolerated in previously treated cancer patients, with no treatment-related deaths, SAE’s, dose modifications, or Grade 4 toxicities on either schedule. There is also no evidence of cumulative or late emerging toxicity, thus far. Grade 1-2 toxicities include nausea, vomiting, stomatitis, abdominal pain, constipation, diarrhea, paresthesia, and fatigue. Cohort expansions are continuing at 4.5 mg/m2 (weekly schedule) and 2.5 mg/m2 (biweekly schedule). Anti-tumor activity with EC1456 is suggested by prolonged stable disease in FR+ patients: 11/20 patients had stable disease as their best study response. EC1456 shows a dose-dependent PK profile that has prolonged drug concentration above IC50 and is more favorable than the 1st generation SMDC, vintafolide. (Original Source)
Shares of Endocyte closed today at $6.03, up $0.0012 0.01%. ECYT has a 1-year high of $9.35 and a 1-year low of $5.01.
On the ratings front, Endocyte has been the subject of a number of recent research reports. In a report issued on March 3, Wedbush analyst David Nierengarten reiterated a Buy rating on ECYT, with a price target of $12, which implies an upside of 99.3% from current levels. Separately, on March 2, Cantor Fitzgerald’s Daniel Brims reiterated a Buy rating on the stock and has a price target of $21.
David Nierengarten and Daniel Brims have a total average return of 53.1% and -2.0% respectively. Nierengarten has a success rate of 61.8% and is ranked #10 out of 3600 analysts!
Smile - well thought out post and quite logical. As for the Investors being burned - it has been over a year and I am sure many institutions that bought into the secondary in March, 2014, still have many of their shares. They EXPECT a payout even if they break even which would be over $20/shr. Also, those Analysts that over covered Endocyte with a PT too high (think Wedbush at $65) need to save some face - forget BREAN as Ashcoff (sp) is a turncoat. Anyway, before we see $20, let's see $7 and get some upward momentum!!